Here’s What Analysts Forecast For Bicycle Therapeutics plc (NASDAQ:BCYC)

TipRanks

Goldman Sachs: These 3 Stocks Are Poised to Surge by at Least 50%

Is it time for the bears to break out the champagne glasses? Not so fast, says Goldman Sachs. Volatility has ruled the Street for the last few weeks, leading some to conclude that those with a more pessimistic outlook had been vindicated, but the firm believes stocks can still climb higher.According to Goldman Sachs’ head of U.S. equity strategy, David Kostin, the S&P 500 could still hit 3,600 by the end of the year, and 3,800 by mid-2021, on the back of vaccine-related optimism and progress with the economic reopening. This would reflect gains of 10% and 16%, respectively, should the index ultimately reach these targets.“Despite the sharp sell-off in the past week, we remain optimistic about the path of the U.S. equity market in coming months. The Superforecaster probability of a mass-distributed vaccine by Q1

Read More

Read More

Future cars may live a lot longer, analysts believe

Fewer major changes save automakers cash.


Chevrolet

We know the song and dance. A new vehicle arrives, it undergoes some typically mild changes after a couple years and then a new generation arrives after five years or so. It’s basically how the modern car industry operates, because new and fresh cars sell. Future cars, however, may live a whole lot longer before they’re replaced outright.

That’s the consensus from analysts who spoke during the Society of Automotive Analysts webinar on Monday. WardsAuto reported on how things could shift in the years to come, especially as more electric cars hit the roads. Since EVs will, essentially, be immune to emissions regulations, there’s even less of an incentive for automakers to make big changes. Couple the zero-emissions powertrain with the emergence of over-the-air updates, and the idea of a 10-year vehicle life cycle doesn’t seem incredibly outrageous.

Read More

Read More

Analysts Set Bicycle Therapeutics Limited (NASDAQ:BCYC) Price Target at $21.30

Shares of Bicycle Therapeutics Limited (NASDAQ:BCYC) have earned a consensus rating of “Buy” from the eight research firms that are presently covering the firm, Marketbeat reports. Three investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $21.30.

Several analysts recently weighed in on the stock. Oppenheimer reiterated a “buy” rating and issued a $27.00 price target on shares of Bicycle Therapeutics in a report on Tuesday, July 21st. Canaccord Genuity restated a “buy” rating and set a $23.50 target price on shares of Bicycle Therapeutics in a report on Tuesday, May 12th. HC Wainwright restated a “buy” rating and set a $25.00 target price on shares of Bicycle Therapeutics in a report on Thursday, August 6th. Zacks Investment

Read More

Read More

O’Reilly Automotive (NASDAQ:ORLY) Earns Hold Rating from Analysts at Oppenheimer

Oppenheimer began coverage on shares of O’Reilly Automotive (NASDAQ:ORLY) in a research report released on Thursday, TipRanks reports. The firm issued a hold rating on the specialty retailer’s stock.

ORLY has been the topic of several other reports. Royal Bank of Canada boosted their target price on O’Reilly Automotive from $437.00 to $505.00 and gave the stock an outperform rating in a report on Tuesday, July 28th. Nomura Instinet boosted their target price on O’Reilly Automotive from $372.00 to $390.00 and gave the stock a neutral rating in a report on Wednesday, May 20th. Bank of America boosted their target price on O’Reilly Automotive from $375.00 to $415.00 and gave the stock a buy rating in a report on Monday, April 20th. UBS Group boosted their target price on O’Reilly Automotive from $430.00 to $470.00 and gave the stock a buy rating in a report on Friday, June 26th. Finally,

Read More

Read More